EVFMOTCPharmaceutical PreparationsFiscal year ends December 31
Evofem Biosciences, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$0.01−0.00 (-10.00%)
Close on Oct 19, 2026
- Market cap
- $865.23K
- P/E (TTM)
- –
- Dividend yield
- –
Evofem Biosciences statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Evofem Biosciences | Industry median |
|---|---|---|
| Market Cap | $834.94K | $164.85M |
| Enterprise Value | $911.94K | $87.06M |
| PS Ratio | 0.05 | 3.60 |
Enterprise value
| Measure | Evofem Biosciences | Industry median |
|---|---|---|
| EV / Sales | 0.05 | 2.43 |
Income (trailing twelve months)
| Measure | Evofem Biosciences | Industry median |
|---|---|---|
| Revenue | $18.05M | $57.94M |
| Gross Profit | $13.63M | $90.47M |
| Operating Income | -$2.76M | -$21.44M |
| Pretax Income | -$15.29M | -$14.45M |
| Net Income | -$15.28M | -$22.46M |
| EBITDA | -$2.76M | -$16.91M |
| EPS (Diluted) | -$0.11 | -$0.83 |
Margins
| Measure | Evofem Biosciences | Industry median |
|---|---|---|
| Gross Margin | 75.5% | 52.3% |
| Operating Margin | -15.3% | -44.5% |
| Pretax Margin | -84.7% | -13.0% |
| Profit Margin | -84.7% | -39.2% |
| EBITDA Margin | -15.3% | -31.3% |
| FCF Margin | -2.64% | -8.85% |
Returns
| Measure | Evofem Biosciences | Industry median |
|---|---|---|
| Return on Assets (ROA) | -139.5% | -41.0% |
Growth
| Measure | Evofem Biosciences | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 4.49% | 6.01% |
| Revenue Growth (3Y CAGR) | 6.23% | 2.25% |
| Revenue Growth (5Y CAGR) | 114.4% | 6.42% |
Balance sheet
| Measure | Evofem Biosciences | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $285.00K | $62.42M |
| Total Debt | $362.00K | $120.13M |
| Net Cash (Debt) | -$77.00K | $15.68M |
| Net Cash Per Share | -$0.00 | $0.66 |
| Equity (Book Value) | -$87.52M | $48.79M |
| Book Value Per Share | -$0.66 | $1.36 |
| Tangible Book Value | -$88.39M | $23.06M |
| Working Capital | -$82.53M | $75.77M |
Financial position
| Measure | Evofem Biosciences | Industry median |
|---|---|---|
| Current Ratio | 0.07 | 3.30 |
| Quick Ratio | 0.03 | 2.39 |
| Interest Coverage | -1.13 | -7.12 |
Cash flow (trailing twelve months)
| Measure | Evofem Biosciences | Industry median |
|---|---|---|
| Operating Cash Flow | -$472.00K | -$12.35M |
| Capital Expenditures | -$5.00K | -$1.06M |
| Free Cash Flow | -$477.00K | -$20.28M |
| FCF Per Share | -$0.00 | -$0.42 |
Efficiency
| Measure | Evofem Biosciences | Industry median |
|---|---|---|
| Asset Turnover | 1.65 | 0.38 |
| Inventory Turnover | 2.18 | 2.67 |
| Revenue Per Employee | $622.24K | $398.96K |
| Profits Per Employee | -$526.97K | -$703.34K |
| Employee Count | 29 | 74 |
Dividends and yields
| Measure | Evofem Biosciences | Industry median |
|---|---|---|
| Earnings Yield | -1830.3% | -22.7% |
| FCF Yield | -57.1% | -9.07% |
Shares
| Measure | Evofem Biosciences | Industry median |
|---|---|---|
| Shares Outstanding | 132,530,000 | 58,179,650 |
| Shares Change (YoY) | -91.7% | 11.1% |
| Shares Change (QoQ) | 0.00% | 0.54% |
| Float | 117,821,000 | 49,173,100 |
| Shares Held by Insiders | 11.1% | 11.6% |
Taxes
| Measure | Evofem Biosciences | Industry median |
|---|---|---|
| Income Tax | -$6.00K | $91.50K |
Scores
| Measure | Evofem Biosciences | Industry median |
|---|---|---|
| Altman Z-Score | -182.09 | -0.24 |
| Piotroski F-Score | 4 | 4 |
Calculated by StockData from Evofem Biosciences's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.